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Abstract
Beta cell failure is one of the most important features of type 2 diabetes mellitus 
(T2DM). High- density lipoprotein (HDL) has been proposed to improve β- cell func-
tion. However, the mechanisms involved in this process are still poorly understood. 
The aim of this study was to investigate the contribution of sphingosine- 1- phosphate 
(S1P) in the impact of HDL treatment on insulin secretion by pancreatic β- cells and to 
determine its mechanisms. Primary cultures of β- cells isolated from rat were treated 
with or without HDL in the presence or absence of S1P pathway inhibitors and insulin 
secretion response was analyzed. The S1P content of HDL (HDL- S1P) isolated from 
T2DM patients was analyzed and correlated to the HDL- induced insulin secretion. 
The expression of genes involved in the biosynthesis of the insulin was also evalu-
ated. HDL as well as S1P treatment enhanced glucose- stimulated insulin secretion 
(GSIS). In HDL isolated from T2DM patients, while HDL- S1P was strongly cor-
related to its pro- secretory capacity (r  =  0.633, p  =  0.005), HDL- cholesterol and 
apolipoprotein AI levels were not. HDL- induced GSIS was blocked by the S1P1/3 
antagonist but not by the S1P2 antagonist, and was also accompanied by increased 
intracellular S1P in β- cells. We also observed that HDL improved GSIS without sig-
nificant changes in expression levels of insulin biosynthesis genes. Our present study 
highlights the importance HDL- S1P in GSIS in T2DM patients and demonstrates that 
HDL induces insulin secretion by a process involving both intra- and extra- cellular 
sources of S1P independently of an effect on insulin biosynthesis genes.
K E Y W O R D S
glucose- stimulated insulin secretion, high- density lipoproteins, primary pancreatic beta cells, 
sphingosine- 1- phosphate, type 2 diabetes mellitus
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1 |  INTRODUCTION
A central feature of the etiology of type 2 diabetes mellitus 
(T2DM) is β- cell failure, involving a deficit in insulin secre-
tion and β- cell apoptosis. Recent studies have highlighted a 
role for HDL in maintaining β- cell function, by attenuating 
the deleterious effects of intracellular stress and limiting β- 
cell apoptosis when the cells are subjected to various condi-
tions of physiological or non- physiological stress (Petremand 
et al., 2012; Roehrich et al., 2003).
There is scarce information on a more direct role of HDL 
in insulin secretion. Current data are controversial with some 
studies showing that HDL treatment can enhance glucose- 
stimulated insulin secretion (GSIS) and other showing no ef-
fect on GSIS (Drew et al., 2009; Rutti et al., 2009). In patients, 
reconstituted HDL (rHDL: apolipoprotein AI + phospholipid 
complex) treatment reduced plasma glucose in T2DM by in-
creasing plasma insulin and activating AMP- activated protein 
kinase in skeletal muscle (Drew et al., 2009). Previous studies 
have focused on the role of its major peptide component apolipo-
protein AI (apoAI) (Cochran et al., 2014; Domingo- Espin et al., 
2016; Fryirs et al., 2010). However, there is growing evidence 
of the importance of a lipid component of HDL, sphingosine- 1- 
phosphate (S1P), to a range of beneficial effects of HDL on the 
vasculature (Sattler & Levkau, 2009). These include promoting 
endothelial integrity and angiogenesis, modulating arterial ves-
sel tone and reducing inflammatory reactions affecting the en-
dothelium. Plasma S1P is principally associated with HDL via 
apolipoprotein M (apoM) (Murata et al., 2000). Recent studies, 
including our own, have shown that S1P contained in the HDL 
particle, (defined in this manuscript by HDL- S1P) is bioactive 
and has direct beneficial effects on several organs, including 
the heart, and notably antiapoptotic actions (Brinck et al., 2016; 
Levkau, 2015; Sattler et al., 2015).
Regarding the impact of the S1P content of HDL (HDL- 
S1P) in T2DM, we recently showed that the concentration 
of HDL- S1P is directly correlated to the capacity of HDL to 
protect cardiomyocytes from oxidative insult (Brinck et al., 
2016). Whether HDL- S1P can influence the impact of HDL 
on pancreatic β- cells remains unknown.
The aim of this study was to analyze the effect of HDL 
and its constituent S1P on the insulin secretion capacity in 
a model of primary culture of rat β- cell and investigate its 
mechanisms of action. A particular aspect was the investiga-
tion of HDL- S1P in HDL isolated from T2DM.
2 |  MATERIAL AND METHODS
2.1 | Participant characteristics
A total number of 18 T2DM patients were prospectively 
recruited at the University Hospitals of Geneva, Service of 
Therapeutic Education for Chronic Diseases. Ethical permis-
sion (Ethics Commission, University Hospital) was accorded 
for the study and informed consent was obtained from all 
donors. All human investigation was conducted according 
to the principles expressed in the Declaration of Helsinki. 
Participant characteristics are given in Table 1. The fol-
lowing clinical parameters were assessed at the University 
Hospital of Geneva: Glucose, Hemoglobin A1c, total choles-
terol, HDL- cholesterol and triglycerides were measured with 
the Cobas e501 automate using electrochemiluminescence 
(Roche). LDL- cholesterol concentrations were calculated ac-
cording to the Friedewald formula. A pool of plasma from 
healthy donors was also used to isolated HDL.
2.2 | Primary Rat β- cell sorting and 
primary culture
The investigation conformed to the Guide for the Care and 
Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85– 23, revised 
1996) and was approved by the local ethical commit-
tee of the Geneva University Medical School. Islets of 
Langerhans were isolated from male rats OFA (200– 250 g, 
7– 8  weeks old) using a standard procedure as described 
(Gosmain et al., 2010). β- cells were separated from α- cells 
and exocrine cells by autofluorescence- activated sorting 
with the FACS Vantage SE cell sorter (Becton Dickinson) 
following 2 criteria: fluorescence intensities and cell size. 
We obtained two major populations characterized by immu-
nohistochemistry, β- cells, and an enriched α- cell fraction. 




Age, years 51 (45– 67.25)
Triglycerides, mmol/L 1.385 (1.16– 2.77)
Total cholesterol, mmol/L 5.05 (3.66– 5.775)
LDL- Ca , mmol/L 2.84 (2.413– 3.815) (n = 17)
HDL- C, mmol/L 1.135 (0.93– 1.468)
Glucose mmol/L 7 (5.775– 8.725)
Hemoglobin A1c, mmol/L 7.59 (6.47– 10.21)
Smokers 4/18
Coronary artery disease 2/18
Systolic blood pressure (mmHg) 131.5 (112.5– 145)
Diastolic blood pressure (mmHg) 82.5 (76.25– 90)
Heart rate (beat/min) 79 (75– 82)
Body mass index (kg/m2) 35.75 (29.775– 44.6)
Median (25– 75 percentile).
aCalculated by Friedewald's formula. 
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Fraction 1 was composed almost exclusively of insulin- 
positive cells (>95%), whereas fraction 2 of a majority of 
glucagon- positive cells (∼75 ± 5%) (Gosmain et al., 2012). 
β- cells were cultured on extracellular matrix- coated plates 
derived from 804G cells (laminin- 5- rich extracellular ma-
trix) in DMEM containing 10% fetal bovine serum (FBS), 
11.2  mM D- glucose, 2  mM l- glutamine, and antibiotics. 
Before stimulation, β- cells were incubated overnight with 
DMEM containing 1% FBS, 5.6 mM D- glucose, 2 mM l- 
glutamine, and antibiotics.
Prior to testing GSIS, β- cells were incubated 24 h with 
or without HDL (400  µg/ml) in DMEM containing 0.5% 
fatty acid- free bovine serum albumin (BSA), 5.6  mM D- 
glucose and antibiotics (see Figure S2 for experimental 
protocol).
2.3 | Measurements of insulin 
secretion and content
Insulin secretion was analyzed by sequential treatment with 
different concentrations of glucose. Briefly, β- cells were first 
incubated for 2 h in depleted medium [Krebs buffer + 2.8 mM 
glucose + 0.1% BSA (KRB- 2.8 mM glc)] to minimize insulin 
secretion. Cells were then incubated for 1 h in KRB- 2.8 mM 
glc to determine basal secretion levels and stimulated by an ad-
ditional 1 h incubation with KRB- 16.7 mM glc. In each experi-
ment, a 2.8 mM glucose concentration is used for basal values 
and 16.7 mM glucose for stimulated values. Insulin cell content 
was measured after cell collection into a freezing acid/ethanol 
mixture. Insulin was quantified by an ELISA kit (High Range 
Rat Insulin ELISA kit Mercodia) following the manufacturer's 
recommendations (see Figure S1 for experimental protocol). 
Inhibitors or antagonists and vehicles were incubated 30 min 
before adding HDL. Sphingosine Kinase Inhibitor II (SK- II, 
10 µM), N,N- Dimethylsphingosine (DMS, 10 µM), VPC23019 
(2 µM, S1P1 and 3 antagonist), and JTE013 (5 µM, S1P2 an-
tagonist) were from Cayman Chemical.
2.4 | Preparation of HDL
For preliminary studies, HDL (d  =  1.063– 1.21  g/ml) was 
prepared by a standard double ultracentrifugation protocol 
from pooled human plasma of healthy donors as described 
(Brinck et al., 2016). This preparation was used in experi-
ments if not otherwise indicated. Subsequently, and notably 
when individual preparations from T2DM patients were re-
quired, a more rapid isolation procedure (7 h) was developed. 
It entailed precipitation of apolipoprotein B containing lipo-
proteins by addition of sodium phosphotungstate (12  mM, 
pH 6.15) and MgCl2 (50  mM) then centrifuging (3500  g, 
1  h, 4°C). The supernatant was recovered and the density 
adjusted to 1.21  g/L with NaBr before ultracentrifugation 
(5 h, 430,000 g). HDL was recovered and dialyzed against 
PBS- EDTA (100 µM) or by several washes with PBS- EDTA 
in microspin columns. HDL protein concentration was de-
termined by Lowry. HDL concentration is expressed as its 
protein concentration.
2.5 | RNA preparation and RT- 
PCR analyses
Total RNA was isolated from primary rat β- cells using an 
RNA isolation kit (Qiagen) and then reverse transcribed. 
Target genes involved in insulin biosynthesis and signalling 
pathways were analyzed by real- time RT- PCR using LC 480 
II (Roche Diagnostics) and specific primers (see Figure S1 
for experimental protocol). Target gene expression was nor-
malized to Rps9 and results expressed in arbitrary units (AU). 
The primers sequences are listed in Table S1. For Sphk1 (Rn 
00682794_g1) and Sphk2 (Rn 01457923_g1) measurement 
Taqman probes (Themofisher) were used and normalized by 
Gapdh (Rn 99999916_s1).
2.6 | HDL- S1P measurement
S1P concentrations in HDL were determined by liquid- 
chromatography tandem mass spectrometry system (LC– MS/
MS). Isolated HDL was diluted 1:9 in MeOH containing 
10 ng/ml internal standard (S1P- d7, Avanti Polar Lipids Inc.) 
prior to injection into the LC– MS/MS (Ultimate 3000 LC 
Series, Thermo Fisher Scientific Inc., and 5500 QTrap® triple 
quadrupole linear ion trap system equipped with a TurboIon 
Spray™ interface (AB Sciex)). Data acquisition and analysis 
were performed using Analyst™ software (version 1.6.2; AB 
Sciex) (Brinck et al., 2016). S1P concentrations in cells were 
determined by liquid- chromatography tandem mass spectrom-
etry system (LC– MS/MS) after 24  h stimulation with HDL. 
Samples were prepared as follow: cells were removed from 
medium and washed three times with cold PBS. Cells were in-
cubated with 1.5 ml solution of ice cold methanol 80% (vol/vol) 
for 20 min, scraped, placed in 2 ml Eppendorf tube and centri-
fuged 14,000g for 5 min at 4°C. The supernatant was collected, 
transferred to a new 2 ml Eppendorf tube and lyophilized using 
no- heat speed vacuum. The pellet was resuspended in 100 µl 
methanol for S1P quantification by LC– MS/MS.
2.7 | S1Pd7 experiments
To evaluate the fate of S1P contained in HDL particle, we used 
a preparation of HDL particle that incorporated S1Pd7 (deute-
rium) which can be specifically identified by LC– MS/MS. We 
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were therefore able to discriminate the S1Pd7 from the endoge-
neous S1P of HDL particle. S1Pd7 was incorporated in native 
HDL as follows; firstly S1Pd7 (methanol 95% (vol/vol)) was 
dried in a glass tube and incubated 45 min, 37°C with HDL 
particles (1 mg/ml) followed by dialysis against PBS- EDTA 
(100  µM) using microspin columns. The incorporation of 
S1Pd7 was confirmed by LC– MS/MS using the same protocol 
as HDL- S1P determination. Six different S1Pd7 concentration 
were evaluated (see Figure S1a for experimental protocol). The 
preparation with comparable amounts of S1P and S1Pd7 was 
chosen for the experiments (see Figure S2b and c).
To evaluate whether S1P contained in HDL particle 
was able to transfer into cultured β- cells, β- cells were in-
cubated 24  h with or without HDL particles (400  µg/ml) 
that contained S1Pd7 in DMEM containing 0.5% free fatty 
acid bovine serum albumin (BSA), 5.6 mm D- glucose and 
antibiotics (see Figure S2d for experimental protocol). At 
the end of the incubation, the medium was collected for 
analysis. Cells were washed three times with cold PBS be-
fore incubation with 1.5 ml of frozen methanol 80% (vol/
vol) for 20 min, scraped, placed in 2 ml Eppendorf tube and 
centrifuged 14,000g for 5 min at 4°C. The supernatant was 
collected, transferred to a new 2 ml Eppendorf tube and lyo-
philized using no- heat speed vacuum. The pellet was resus-
pended in 50 µl methanol. The amounts of S1Pd7 and S1P 
were analyzed in the medium and the pellet, correspoding to 
cell content, by LC– MS/MS.
2.8 | Statistical analysis
Values are presented as mean ± SEM if not otherwise stated. 
Differences between data sets were assessed by Student's 
t- test (paired where applicable) or two- way ANOVA with 
Tukey's  multiple comparison post- test, Pearson product- 
moment correlation coefficient (Pearson's r). A value of 
p < 0.05 was considered significant.
3 |  RESULTS
3.1 | Insulin secretion induced by HDL
Consistent with other reports, our GSIS analysis performed on 
pancreatic β- cells revealed that treatment with HDL (400 µg/
ml) for 24 h doubled insulin secretion compared to non- treated 
cells (control) (Figure 1a). Treatment with HDL 200 µg/ml 
was borderline significant (p = 0.06) (see Figure S3). HDL 
was not present during GSIS. Of note, cell insulin content was 
similar between the two groups; (378.5 ± 55 µg/L in control 
vs. 428.2 ± 103 µg/L in HDL- treated cells, (p = 0.58), data 
not shown). The absolute amount of basal insulin secretion 
was not different between the two groups (2.0 ± 0.5 µg/L in 
control vs. 2.7 ± 1.4 µg/L, p = 0.80). We also confirmed, in 
our model, previous suggestions that S1P (400 nM) by itself 
can increase insulin secretion (Figure 1b).
3.2 | S1P content in HDL correlates with the 
level of insulin secretion in T2DM patients
Our recent studies (Brinck et al., 2016) have highlighted the 
importance of the HDL- S1P to HDL function in T2DM. We 
therefore analysed a potential role for S1P in HDL- induced 
GSIS. To examine the relevance of S1P in HDL in our model, 
we analysed HDL- induced GSIS as a function of HDL- S1P 
concentration using HDL preparations from T2DM patients. 
The characteristics of diabetic patients are shown in Table 1. 
F I G U R E  1  HDL and S1P treatment improves insulin secretion. 
HDL 400 µg/ml treatment for 24 h improved GSIS (n = 8) (a). 
S1P 400 nM treatment for 24 h improved GSIS (n = 4) (b). Data 
are mean ± SEM, statistical p value was calculated using a two- 
way ANOVA with Tukey's multiple comparison post- test. 2.8 mM 
glucose was compared to respective 16.7 mM glucose and considered 
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As shown in Figure 2, the level of insulin secretion was directly 
correlated to the amount of S1P in HDL (Figure 2a), but not to 
HDL- cholesterol (HDL- C) (Figure 2b) or apoAI (Figure 2c). 
Our results show for the first time that while the content of S1P 
reflects the GSIS potential of HDL, apoAI or HDL- C do not.
3.3 | S1P is required for HDL- induced GSIS 
improvement
The specific role of S1P was further evaluated by focusing 
on S1P receptor subtypes. Cells were incubated with specific 
antagonists 30  min before HDL treatment. The expression 
of S1P receptor subtypes in our model of primary beta cells 
measured (see Figure 3a). We focused on S1P1, S1P2, and 
S1P3 as they are the subtype that have been implicated in the 
effects of S1P. In these experiment we determined whether 
the impact of HDL was significantly reduced when the cells 
were treated with the antagonists. While incubation with the 
S1P1/3 antagonist (VPC23019, 2 µM) significantly reduced 
the pro- secretory effect of HDL (HDL vs. VPC  +  HDL, 
p = 0.028), the S1P2 antagonist (JTE013, 5 µM) had no sig-
nificant effect (HDL vs. JTE + HDL, p = ns), as HDL treat-
ment still enhanced GSIS. Interestingly, treatment with the 
S1P2 antagonist alone significantly diminished insulin secre-
tion induced by GSIS (control vs. JTE, p = 0.013), (Figure 3).
S1P is a bioactive lipid with intra- and extra- cellular ef-
fects. S1P can be generated intracellularly from sphingosine 
by two different isoforms of sphingosine kinase (sphk): sphk1 
and sphk2. We treated cells with the sphk1 specific inhib-
itor, SK- II (10  µM) or the non- specific sphk inhibitor N,N- 
dimethylsphingosine (DMS, 10  µM) 30  min before adding 
HDL for 24 h. The enhancement of GSIS induced by HDL 
treatement was significantly abolished in the presence of DMS 
(HDL vs. DMS + HDL, p = 0.020) but not SK- II (HDL vs. 
SKII + HDL, p = ns) (Figure 4) demonstrating that inhibi-
tion of sphk1 is not sufficient for inhibiting the pro- secretory 
impact of HDL treatment. This demonstrates an involvement 
of intracellular S1P formation by sphingosine kinase and sug-
gests a role for sphingosine kinase 2 in this response. The ex-
pression of sphk1 and sphk2 mRNA was analysed after HDL 
treatment but neither was significantly changed after 24 h of 
treatment with HDL (see Table 2). Using LC- MS/MS anal-
ysis, we quantified the concentration of intracellular S1P. It 
showed a significant increase after HDL treatment (see Figure 
5a). We used S1Pd7 to elucidate the origin of intracellular S1P 
(see Figure S2). β- cells were treated with control or HDL con-
taining S1Pd7 (HDL- S1Pd7) and the fate of S1Pd7 after 24 h 
of stimulation was determined (see Figure 5). As expected, 
while the control medium contained no S1P and no S1Pd7, 
the HDL- SD1Pd7 medium contained a similar amount of S1P 
and S1Pd7. We also measured the amount of intracellular S1P 
and S1Pd7. S1P found in control cells represented the intracel-
lular amount of S1P. In HDL- S1Pd7- treated cells, S1P con-
centration was significantly increased and S1Pd7 was found 
in the cells (see Figure 5). The results demonstrated that the 
major amount of S1Pd7 remained with HDL, but a fraction 
was transferred to cells. Presuming that the same amount of 
S1P (approximately 20%) was also transferred into the cells, 
this amount can explain the increase in intracellular S1P level 
found after HDL treatment. The experiments with sphk inhib-
itor and with S1Pd7 revealed (i) the important role of S1P in 
HDL- induced insulin secretion as the effect of HDL is abol-
ished by DMS and (ii) the incorporation of S1P from the HDL 
particle may explain the increase in intracellular levels of S1P. 
F I G U R E  2  HDL S1P content from diabetic patients correlates 
with pro- secretory capacity Pancreatic β- cells were incubated with HDL 
(400 µg/ml) from diabetic patients (n = 18) for 24 h and insulin secretion 
was evaluated following the GSIS protocol. The effects were correlated 
to the HDL S1P content. (a) Correlation between Insulin secretion and 
HDL- cholesterol. (b) Correlation between Insulin secretion and apoAI. 
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To our knowledge, these data demonstrate, for the first time, 
that HDL treatment can directly modulate intracellular S1P 
levels in pancreatic β- cells.
3.4 | Expression of insulin biosynthetic and 
oxidative stress genes
Several mechanisms have been proposed to explain the effect 
of HDL on GSIS. We analysed the expression of genes impli-
cated in the insulin secretion process (for protocol see Figure 
F I G U R E  3  HDL treatment improves insulin secretion via S1P 
1/3. RNA expression of S1P receptors subtypes quantified by qPCR, 
normalized by Rps9 expression and expressed in arbitrary unit (AU). 
S1P3 expression is increased compared to other S1P receptor subtypes. 
Data are mean ± SEM, statistical p value was calculated using a 
one- way ANOVA with Tukey's multiple comparison post- test. S1P 
1/3 antagonist (VPC23019, 2 µM) (b) and S1P2 antagonist (JTE013, 
5 µM) (c) were incubated 1 h before treatment with HDL 400 µg/
ml. Graphs represented GSIS and data are mean ± SEM, statistical p 
value was calculated using a two- way ANOVA with Tukey's multiple 
comparison post- test. 2.8 mM glucose (basal) was compared to 
respective 16.7 mM glucose (stimulated) and considered significantly 














































































































































































































F I G U R E  4  HDL treatment improves insulin secretion via Sphk2. 
Nonspecific Sphk inhibitor (DMS, 10 µM) (a) and Sphk1 inhibitor 
(SK- II, 10 µM) (b) were incubated 30 min before treatment with or 
without HDL (400 µg/ml). Graphs represented GSIS and data are 
mean ± SEM, statistical p value was calculated using a two- way 
ANOVA with Tukey's multiple comparison post- test. 2.8 mM glucose 
(basal) was compared to respective 16.7 mM glucose (stimulated) 
and considered significantly different with a p value of * <0.05, 
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S1b). These included expression of Insulin, the transcription 
factors MafA, pancreatic and duodenal homeobox 1 (Pdx1), 
paired box 6 (Pax6) and the enzymes proprotein convertase 1 
(Pc1) and proprotein convertase 2 (Pc2). As shown in Table 
2, there were no significant difference between control and 
HDL- treated cells. This result suggests that HDL stimulates 
GSIS but not insulin biosynthesis (Table 2).
Further analyses were undertaken to evaluate the expres-
sion of genes involved in β- cell development (Homeobox 
protein Nkx- 6.1), proliferation (microtubule nucleation factor 
Tpx2, Antigen Ki67) as well as oxidative stress (Dna dam-
age inducible transcript 3 (Ddit3), Bcl2 binding component 3 
(Bbc3), Heat shock protein family a member 5 (HspA5), Dna 
topoisomerase 2- alpha (Top2A)). The expression of all the 
genes remained unchanged after 24  h treatment with HDL 
(Table 2). Thus, the cultured β- cells did not show evidence of 
stress that could impact on their capacity to secrete insulin.
4 |  DISCUSSION
The beneficial impact of HDL on pancreatic β- cells in T2DM 
patients was highlighted by (Drew et al., 2009). Infusion of 
rHDL improved glucose levels by an increase in insulin se-
cretion and glucose uptake by muscle (Drew et al., 2009). 
These results were confirmed in clinical and experimental 
models, where rHDL, apoAI, and HDL treatment increased 
insulin secretion and decreased circulating glucose (Drew 
Name of gene Control HDL treated
p 
value
Sphk1 0.000017 ± 9.4E−06 0.000024 ± 7.7E−06 0.059
100% 153.4 ± 45.8%
Sphk2 0.0194 ± 0.0119 0.0209 ± 0.0108 0.352
100% 104.6 ± 7.5%
MafA 0.198 ± 0.019 0.169 ± 0.007 0.402
100% 88.8 ± 24%
Pdx1 0.273 ± 0.088 0.241 ± 0.073 0.573
100% 91.7 ± 28.2%
Pax6 0.294 ± 0.039 0.241 ± 0.008 0.336
100% 87.7 ± 29.2%
Pc1 0.132 ± 0.01 0.109 ± 0.012 0.467
100% 78 ± 15.9%
Pc2 2.766 ± 0.098 2.315 ± 0.205 0.282
100% 90.9 ± 19.3%
Nkx6.1 0.201 ± 0.017 0.176 ± 0.005 0.491
100% 92.9 ± 34.6%
Tpx2 0.012 ± 0.0003 0.0011 ± 0.0003 0.693
100% 99.7 ± 12.4%
Ki67 0.005 ± 0.0012 0.0046 ± 0.0017 0.718
100% 90.1 ± 34.7%
Ddit3 0.248 ± 0.0285 0.264 ± 0.0327 0.106
100% 102.2 ± 3.6%
Bbc3 0.0052 ± 0.0001 0.0050 ± 0.0004 0.639
100% 106.8 ± 15.1%
HspA5 0.8592 ± 0.02 0.8236 ± 0.061 0.500
100% 86.3 ± 8.9%
Top2A 0.0014 ± 0.0001 0.0013 ± 0.0001 0.794
100% 83.6 ± 34.4%
The expressions of target genes were evaluated 24 h after HDL treatment (400 µg/ml). No significant 
differences were found between non- treated (control) and HDL treated cells.
Gene expression (arbitrary units, AU) normalized by the expression of the Rps9 gene.
Control treated cells are considered 100% and the respective percentage ± standard deviation, statistical p 
value was calculated using Student- T test.
T A B L E  2  Gene expression
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et al., 2009; Rye et al., 2016; Siebel et al., 2015). The au-
thors concluded that effects of HDL on pancreatic β- cells 
were principally explained by a protective impact on cell 
survival against stress- induced apoptosis, as promoted by 
high glucose concentrations and cytokines (Petremand et al., 
2009, 2012; Rutti et al., 2009). A direct role for HDL in insu-
lin secretion has been poorly explored although some studies 
propose a role for apoAI (Rye et al., 2016). We observed 
no correlation between circulating apoAI and insulin secre-
tion, contrary to our observation with HDL- S1P. It should be 
noted with respect to infusion studies that rHDL can rapidly 
assimulate S1P (Brinck et al., 2018) that may alter the com-
position of rHDL in such studies.
S1P has already been implicated in several actions at-
tributed to HDL. In a previous study, we showed that HDL- 
S1P content was associated with the cardioprotective capacity 
of HDL (Brinck et al., 2016). In the current study, we found 
that the insulin pro- secretory capacity of HDL was directly 
associated with the HDL- S1P content in T2DM patients. 
Interestingly, low HDL- S1P has been linked to increased in-
cidence of coronary artery disease and T2DM (Barter et al., 
2007; Besler et al., 2011; Brinck et al., 2016; deGoma et al., 
2008; Kontush & Chapman, 2006; Levkau, 2015). So far, the 
direct role of S1P in insulin secretion has not been investi-
gated in detail.
This study implicates for the first time both extracellular 
and intracellular S1P in HDL- induced insulin secretion from 
pancreatic β- cells. HDL- induced secretion is reduced (i) at 
the extracellular level by blocking S1P receptors (ii) and at 
the intracellular level by blocking S1P synthesis. In the lat-
ter context, HDL was shown to increase β- cell S1P levels, 
mainly via a transfer from the HDL particle. It implies a role 
for an HDL- mediated increased intracellular S1P in the insu-
lin secretory process.
Limited data have suggest that intracellular S1P content 
plays a role in GSIS in cultured β- cells with sphingosine ki-
nase 2 being involved in this process (Cantrell Stanford et al., 
2012; Ng et al., 2017; Shimizu et al., 2000). Our results con-
cur with these suggestions. In addition, using S1Pd7, we 
were able to highlight the transfer of S1P from HDL particle 
into β- cells. We conclude that the origin of the intracellular 
S1P could be the uptake from HDL particles. While further 
investigations are needed to clarify the specific pathway in-
volved in HDL- induced insulin secretion, our results suggest 
that intracellular S1P levels might play a role. This could 
be via an increase in intracellular Ca2+ levels, since the cal-
cium influx rate is crucial for insulin exocytosis (Henquin, 
2011; Rorsman et al., 2012) and modulation of the intracel-
lular S1P level in β- cells has been shown to affect calcium 
levels (Hahn et al., 2017). In addition, Lee and colleagues 
demonstrated that S1P transported in HDL is biologically 
active and is a major effector of HDL- mediated increase in 
intracellular calcium with SRB1 and the S1PR1 and S1PR3 
receptors being required (Lee et al., 2017).
Concerning the role of S1P receptors, Japtok et al. 
showed that pharmacological S1P2 inhibition can reduce 
insulin secretion independently of HDL (Japtok et al., 
F I G U R E  5  HDL transfert S1P into pancreatic β- cells.Pancreatic 
β- cellswere incubated with HDL 400 μg/ml for 24 h and S1P 
cellcontent was quantified by LC MS/MS (a). Data are mean ± SEM, 
statistical p value was calculated using Student- T test paired (n = 4). β- 
cells were treated with control medium (DMEM glucose 5.6 mmol/L, 
0.5%BSA) or with control containing HDL- S1Pd7 (400 µg/ml) (see 
Figure S2). After 24 h of stimulation, S1P and S1Pd7 concentrations of 
incubation medium (b) and cells (c) were determined by LC– MS/MS. 
AUC: area under the curve. Data are mean ± SEM, statistical p value 
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2015). We confirmed these results for basal insulin secre-
tion in the absence of HDL, which was decreased in the 
presence of the S1P2 antagonist, JTE013. However, the 
pro- secretory effects induced by HDL were significantly 
reduced by the S1P1/3 antagonist VPC23019, but not 
significantly by the S1P2 antagonist, JTE013. The effect 
of HDL may mainly involve S1P3, which is the most ex-
pressed S1P receptor subtype in primary pancreatic beta 
cells (18 fold higher than S1P1; see Figure 3a).
We were unable to demonstrate any effects of HDL on 
genes involved in insulin biosynthesis. These results differ 
from Cochran and colleagues who demonstrated that HDL 
treatment on MIN6 increase the expression of Insulin 1, 
Insulin 2, Insulin receptor substrate 1 (Irs1), Insulin recep-
tor substrate 2 (Irs2) and Pdx1 (Cochran et al., 2014). The 
expression of Insulin and Pdx1 remained unchanged in our 
model. This discrepancy may be explained by our use of pri-
mary cultured β- cells compared to a derived cell line. We 
also investigated the expression of target genes involved in 
cell homeostasis and stress- response. Interestingly, we found 
no difference between conditions. As our studies do not im-
plicate increased insulin synthesis or improved cell survival 
as mechanisms in our model of HDL- induced insulin secre-
tion, it suggests an alternative pathway mediated by S1P.
In conclusion, the present manuscript demonstrates that 
HDL induces an increase of GSIS by β- cells independently of 
an effect on insulin biosynthesis and requires both intra- and 
extra- cellular sources of S1P. We observed a strong correla-
tion between HDL- S1P and insulin secretion. We thus high-
light the importance of the S1P- content of HDL in insulin 
secretion. HDL- S1P may promote insulin secretion directly, 
as demonstrated in this current study. Our observations also 
raise the question of whether HDL- S1P could be used to 
evaluate the insulin secretion capacity of HDL particle.
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